Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:CALT NASDAQ:DBVT NASDAQ:OLMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$14.76-0.9%$14.53$12.30▼$20.90$312.23M0.8270,215 shs81,203 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/ADBVTDBV Technologies$16.04+0.1%$19.57$8.50▼$26.18$949.11M-0.99218,705 shs297,778 shsOLMAOlema Pharmaceuticals$9.82-6.0%$14.17$3.89▼$36.26$912.78M1.981.28 million shs1.79 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+4.86%+2.90%-1.06%-8.76%+20.76%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%0.00%DBVTDBV Technologies+0.19%-12.07%-18.75%-22.60%+84.68%OLMAOlema Pharmaceuticals+4.92%-2.25%-29.87%-33.06%+138.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$14.76-0.9%$14.53$12.30▼$20.90$312.23M0.8270,215 shs81,203 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/ADBVTDBV Technologies$16.04+0.1%$19.57$8.50▼$26.18$949.11M-0.99218,705 shs297,778 shsOLMAOlema Pharmaceuticals$9.82-6.0%$14.17$3.89▼$36.26$912.78M1.981.28 million shs1.79 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+4.86%+2.90%-1.06%-8.76%+20.76%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%0.00%DBVTDBV Technologies+0.19%-12.07%-18.75%-22.60%+84.68%OLMAOlema Pharmaceuticals+4.92%-2.25%-29.87%-33.06%+138.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 1.33Sell$12.00-18.70% DownsideCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/ADBVTDBV Technologies 2.88Moderate Buy$48.50202.37% UpsideOLMAOlema Pharmaceuticals 2.71Moderate Buy$44.10349.08% UpsideCurrent Analyst Ratings BreakdownLatest AMRN, CALT, OLMA, and DBVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026OLMAOlema Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/18/2026AMRNAmarin Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2026OLMAOlema Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$38.00 ➝ $35.005/4/2026DBVTDBV Technologies GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$51.005/1/2026DBVTDBV Technologies CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/1/2026DBVTDBV Technologies Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$47.00 ➝ $55.004/21/2026OLMAOlema Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026AMRNAmarin Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/2/2026AMRNAmarin Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/27/2026DBVTDBV Technologies Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$45.00 ➝ $47.003/27/2026DBVTDBV Technologies GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$51.00(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$213.65M1.45$0.36 per share41.25$22.07 per share0.67CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74DBVTDBV Technologies$5.64M168.39N/AN/A$4.20 per share3.82OLMAOlema PharmaceuticalsN/AN/AN/AN/A$5.88 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$38.80M-$0.65N/AN/AN/A-15.51%-2.99%-2.07%7/29/2026 (Estimated)CALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/ADBVTDBV Technologies-$146.95M-$4.46N/AN/AN/A-2,895.37%-129.88%-88.84%7/29/2026 (Estimated)OLMAOlema Pharmaceuticals-$162.45M-$2.02N/AN/AN/AN/A-46.00%-41.22%8/10/2026 (Estimated)Latest AMRN, CALT, OLMA, and DBVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026OLMAOlema Pharmaceuticals-$0.52-$0.52N/A-$0.52N/AN/A4/30/2026Q4 2025DBVTDBV Technologies-$0.14-$0.56-$0.42-$0.55$1.11 million$0.90 million3/26/2026Q4 2025DBVTDBV Technologies-$0.1935-$1.15-$0.9565-$4.43$1.06 million$0.64 million3/16/2026Q4 2025OLMAOlema Pharmaceuticals-$0.51-$0.50+$0.01-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.482.46CALTCalliditas Therapeutics AB (publ)9.442.692.59DBVTDBV TechnologiesN/A4.764.76OLMAOlema Pharmaceuticals0.0110.8810.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%CALTCalliditas Therapeutics AB (publ)2.83%DBVTDBV Technologies71.74%OLMAOlema Pharmaceuticals91.78%Insider OwnershipCompanyInsider OwnershipAMRNAmarin4.21%CALTCalliditas Therapeutics AB (publ)2.20%DBVTDBV Technologies1.06%OLMAOlema Pharmaceuticals12.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.97 million20.09 millionOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionNo DataDBVTDBV Technologies8059.21 million58.58 millionOptionableOLMAOlema Pharmaceuticals7087.35 million76.38 millionOptionableAMRN, CALT, OLMA, and DBVT HeadlinesRecent News About These CompaniesOlema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9 at 10:05 PM | seekingalpha.comLifeSci Capital Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)June 8 at 1:50 PM | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), Jade Biosciences (JBIO) and Oculis Holding (OCS)June 8 at 1:50 PM | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA) and Agios Pharma (AGIO)June 4, 2026 | theglobeandmail.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2026 | globenewswire.comOlema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration ...May 26, 2026 | markets.businessinsider.comOlema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate CancerMay 26, 2026 | globenewswire.comOlema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation GapMay 25, 2026 | finance.yahoo.comOlema Highlights Encouraging OP-3136 Phase 1 Oncology ResultsMay 22, 2026 | theglobeandmail.comOlema Oncology sees early hope as cancer drug shows tumor shrinkage in phase 1 studyMay 22, 2026 | msn.comOlema Pharmaceuticals Reports Promising Initial Data for OP-3136 in Phase 1 Study Evaluating KAT6 Inhibitor for Advanced Solid TumorsMay 21, 2026 | quiverquant.comQOlema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual MeetingMay 21, 2026 | globenewswire.comLifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)May 19, 2026 | theglobeandmail.comOlema Oncology to Participate in Upcoming Investor ConferencesMay 19, 2026 | globenewswire.comOlema: The Market Overreacted To Roche's SERD FailureMay 15, 2026 | seekingalpha.comOlema Oncology Reports First Quarter 2026 Financial and Operating ResultsMay 12, 2026 | markets.businessinsider.comOlema Pharmaceuticals inc Ordinary Shares OLMAMay 10, 2026 | morningstar.comMAssessing Olema Pharmaceuticals (OLMA) Valuation After Adding Dr. Prakash Raman To The BoardMay 10, 2026 | finance.yahoo.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | globenewswire.comOlema Pharmaceuticals Adds Veteran Director to Support GrowthApril 29, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMRN, CALT, OLMA, and DBVT Company DescriptionsAmarin NASDAQ:AMRN$14.76 -0.13 (-0.87%) Closing price 04:00 PM EasternExtended Trading$14.32 -0.44 (-2.98%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 06/9/2026Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.DBV Technologies NASDAQ:DBVT$16.04 +0.01 (+0.06%) Closing price 04:00 PM EasternExtended Trading$16.01 -0.03 (-0.18%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Olema Pharmaceuticals NASDAQ:OLMA$9.82 -0.63 (-6.03%) Closing price 04:00 PM EasternExtended Trading$9.82 +0.00 (+0.05%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Biggest Opportunity From SpaceX’s IPO May Surprise You Chewy’s Growth Engine Is Stronger Than the Market Thinks Everpure: AI Storage Uncertainty Overshadows Breakneck Growth This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason FuelCell Energy Just Got a Wake-Up Call From Wall Street Intel Is the Market's Most Mispriced AI Hedge Palantir's AIPCon Shows Why Customers Are Fueling the Bull Case Uranium Energy Corp Melts Down—Nuclear Opportunity at Hand Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
